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Multiple sclerosis (MS) is a complex disease that seems to depend
on several pathophysiological processes. Because of its varied
clinical presentation, natural history, and response to therapeutic
interventions, MS can be considered to be a group of diseases that
have not been yet characterized, thus resulting in difficult evalu-
ation of prognosis. In the last few years, the role of autoAbs in MS
has been reevaluated, and, therefore, their identification as spe-
cific biomarkers became a relevant target. In this paper, we
demonstrate that an aberrant N-glucosylation is a fundamental
determinant of autoAb recognition in MS. Thus, we developed
CSF114(Glc), an antigenic probe accurately measuring IgM autoAbs
in the sera of a patient population, as disease biomarker. The
relevance of CSF114(Glc) is demonstrated by its clinical application
and correlation with disease activity and prognosis. In fact,
CSF114(Glc), a structure-based designed glycopeptide, is able to
recognize, by ELISA, the presence of specific IgM autoAbs in the
sera of a MS patient population but not in blood donors and other
autoimmune conditions. AutoAbs specific for CSF114(Glc) isolated
from MS patients recognized myelin and oligodendrocyte antigens
by immunohistochemistry but not other nonrelevant tissues. We
demonstrate that CSF114(Glc) is a reliable, specific probe in a
longitudinal study of untreated MS patients. Development of
IgGIgM anti-CSF114(Glc) Abs paralleled clinical activity and brain
lesions positive to MRI. Therefore, a CSF114(Glc)-based immuno-
assay on sera may have important prognostic value in monitoring
MS disease progression guiding optimal therapeutic treatment.
aberrant glycosylation  prognostic probe  synthetic antigen  -hairpin
Multiple sclerosis (MS), the most frequent chronic inflamma-tory demyelinating disease of the CNS, is the most common
cause of disability in young adults. Most cases are diagnosed
between the ages of 20 and 40, with a higher incidence in women.
It is estimated that it affects over one million people worldwide.
Cruelly, although not considered a life-shortening disease, MS
tends to strike people at the prime of their lives, often interrupting
or even terminating their careers (1). Therefore, the disease has a
large social impact, with spiraling costs increasing with the pro-
gression of disability (2). If progression can be delayed, the quality
of life and independence of MS patients will improve and the cost
to health care system and society will decrease accordingly (3).
Thus, an early prognosis could facilitate such a delay in progression.
Although an autoimmune mechanism against CNS myelin anti-
gens (Ags) is thought to contribute to the immunopathological
mechanism of the disease, the target Ags remain elusive. MS is an
heterogeneous disease, particularly in its clinical subforms, with an
extremely variable evolution over time. Because of its varied clinical
presentation, natural history, and response to therapeutic interven-
tions, MS may be considered to be a group of diseases. Lucchinetti
et al. (4) proposed four distinct patterns of MS pathology: (i)
cell-mediated demyelination, (ii) Ab-mediated demyelination, (iii)
active myelin destruction, and (iv) oligodendrogliopathy or oligo-
dendrocyte dystrophy. In the absence of specific biomarkers, the
diagnosisprognosis of MS continues to rely on clinical history,
neurological examination, and paraclinical evidences of temporal
and spatial dissemination of CNS lesions. Nevertheless, the use of
MRI has had a major impact, allowing the early, precise diagnosis
of the disease (5, 6). Recently, it has been stated that a single
diagnostic probe for MS is unlikely to serve as a general prognostic
tool to cover the full clinical spectrum of MS. Therefore, the
development of a number of biomarkers, each one specific for
different pathophysiological mechanisms, will be important for
better understanding disease pathogenesis and for future drug
development in MS (7).
Themost extensively studied putative self-Ags are components of
normal CNS myelin [myelin basic protein (MBP); proteolipid
lipoprotein, and myelin oligodendrocyte glycoprotein (MOG)],
mostly posttranslationally modified proteins (8, 9). Posttransla-
tional modifications can mask self-Ags, creating new Ags no longer
recognized by the immune system. In particular, aberrant glycosyl-
ation affects the immune response and profoundly affects immune
tolerance (10). Recently, IgM autoAbs to recombinant MOG (11,
12) have been reported to be predictors of clinically definite MS
after a first demyelinating event. However, these results need to be
confirmed (13, 14).
New candidate biomarkers in MS could emerge from multi- and
interdisciplinary efforts and the application of novel unbiased
discovery tools (7). With this consideration in mind, we pursued an
approach to develop a specific antigenic probe that will allow
identifying a population of MS patients in which presence of
autoAbs, recognizing the antigenic probe, will correlate with dis-
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ease activity. In fact, the efficient detection of autoAbs in a large
group ofMS patients guided the selection of an optimized synthetic
glycopeptideAg. This approach represents a radical departure from
the conventional methods based on preselected myelin compo-
nents, which displayed variable efficiency in the recognition prop-
erties for autoAbs. Whereas the traditional approach fails to detect
posttranslational modifications of myelin proteins, ours overcomes
these difficulties by using Abs circulating in serum and pathologi-
cally developed in an MS patient subgroup.
In light of the importance of specific sugars and conformation of
epitopes involved in autoAb recognition, we have designed syn-
thetic glycopeptides, and studied their capacity to recognize auto-
Abs in MS patients. The aim of this study is to develop a specific
antigenic probe and a simple assay, both optimized to efficiently
recognize autoAbs characteristic to a subgroup of MS patients.
Selection of the optimized antigenic probe, which is well charac-
terized chemically, was achieved by designing and screening syn-
thetic libraries of glycopeptides. The main advantage of measuring
the autoAb titer in serum through an ELISA, based on a synthetic
probe, is its simplicity and the possibility to perform serial analyses.
Methods
Peptide and Glycopeptide Synthesis. The synthesis of glycopeptides
requires specialized methods (15). All of the products described
have been successfully synthesized by using differently glycosylated
amino acids (16, 17) as building-blocks in an optimized solid-phase
peptide synthesis strategy on an automatic synthesizer (APEX 396,
Advanced ChemTech) following the fluorenylmethoxycarbonyl
tert-butyl strategy (see Supporting Materials and Methods, which is
published as supporting information on the PNAS web site). All
peptides and glycopeptides (Table 1) were obtained with a purity
98% by preparative HPLC (Waters 600), and were characterized
by HPLC electrospray ionization mass spectroscopy (LCQ Advan-
tage, ThermoFinnigan, San Jose, CA) (see Table 3, which is
published as supporting information on the PNAS web site).
CD and NMR Studies.The far-UVCDspectrawere acquired by using
a model J-810 spectropolarimeter (Jasco). Four scans were ac-
quired over 190–260 nm in 0.2-nm steps, with a bandwidth of 1 nm
at 298K. Peptides 3 and 8–11 and the corresponding unglycosylated
3, 8–11 were analyzed in water and in waterhexafluoroacetone
(HFA) at a 1:1 (vol:vol) ratio. NMR spectra were recorded on a
DRX-600 spectrometer (Bruker, Billerica, MA). One-dimensional
NMR as well as DQF-COSY, TOCSY, and NOESY experiments
were run according to protocols described in ref. 17. Structural
determinations and computational modeling procedures can be
found in Supporting Materials and Methods.
Patients.We tested a total of 250 relapsing–remittingMS (RR-MS)
patients classified according to the Poser’s criteria (18). Patients
were between 20 and 60 years of age (median, 34 years of age), had
an expanded disability status scale (EDSS) range from 0 to 6
(median, 2.5), and a disease duration between 1 month and 30
years (median, 9 years). All patients had IgG oligoclonal bands in
cerebrospinal fluid and MRI findings typical of MS.
Furthermore, in a longitudinal follow-up study, we tested 40
RR-MS patients characterized by an EDSS of 3.5 who received
no therapy at the time of the sampling. As controls, we used normal
blood donors (NBD) (n  166); patients with inflammatory
neurological diseases (IND) (n 25), i.e., meningitisencephalitis;
and patients affected by other autoimmune diseases (OAD) (n 
90), i.e., rheumatoid arthritis (n  49), and systemic lupus ery-
thematosus (n  41). All experiments were performed in compli-
ance with institutional guidelines and were approved by the local
hospital’s ethical committees.
Detection of AutoAbs. We assessed the Ab responses against pep-
tides and glycopeptides by solid-phase noncompetitive ELISA
(SP-ELISA) with anti-human IgM or IgG Fab2-specific affinity-
purified Abs conjugated to alkaline phosphatase. In parallel ex-
periments, subclass-specific anti-IgG conjugateswere used to detect
the IgG Abs subclasses. Within- and between-assays coefficients of
variations were 10% (see Supporting Materials and Methods).
Measurement of Ab Affinity by Competitive ELISA and Statistical
Analysis. Ab affinity and Ab affinity heterogeneity were measured
by following the methods published in ref. 19. The semisaturating
dilution was calculated from the preliminary titration curves (ab-
sorbance, 0.7). At this dilution, Abs were preincubated with in-
creasing Ag concentration (1 h at 25°C). Unblocked Abs were
revealed by ELISA, and the antigenic probe concentration–
absorbance relationship was presented graphically. The mean titers
of IgM or IgG autoantibodies positively recognizing the antigenic
probe in MS patients and controls were studied with the Mann–
Whitney U test. The significance of P values was set at 0.001.
Immunoaffinity Columns. CSF114(Glc), dissolved in 0.1 M
NaHCO3 containing 0.5 M NaCl, pH 8.3, was coupled to
CNBr-Sepharose matrix. Sera from MS patients positive to
CSF114(Glc) (diluted 1:10 in PBS) were loaded onto the column
preequilibrated with PBS, pH 7. Adsorbed Abs were eluted by
using 0.1 M glycine, pH 2.6. CSF114(Glc)-specific Abs were
analyzed by UV spectroscopy. The efficiency of this immuno-
adsorbtion was confirmed by SP-ELISA.
Immunohistochemistry. Immunohistochemistry was performed on
sections from human CNS autopsies as well as from other tissues
autopsies (lung, liver, kidney, and lymph node), or biopsies (sural
nerve and muscle) obtained from patients without neurological
diseases as described in ref. 20. These sections were incubated
overnight at 4°C with patients’ sera (diluted 1:800 in PBS) or
IgGIgM purified by CSF114(Glc)-Sepharose affinity columns
(1:10). As controls, we used purified IgMand biotinylated IgG from
CSF114(Glc)-negative cases as well as Ig fractions obtained after
depletion of CSF114(Glc)-specific Ig. Biotinylation of anti-
CSF114(Glc) IgG was performed as described in ref. 21. Double
immunofluorescence was performed with the neural phenotypic
markers MBP (1:200) for mature oligodendrocytes, glial fibrillary
acidic protein (1:500) for astrocytes, CD68 formicroglia (1:100) (all
from DAKO) and NG2 (1:100; Chemicon) for oligodendrocyte
precursors (see Supporting Materials and Methods).
Table 1. Glycosylated and unglycosylated peptides synthesized
as candidate specific multiple sclerosis antigenic probe
Name (peptide no.) Peptide sequence
[Asn31(Glc)]hMOG(30–50) (1) KN(Glc)ATGMEVGWYRPPFSRVVHL
hMOG(30–50) (1) KNATGMEVGWYRPPFSRVVHL
[Asn84(Glc)]hMBP(83–99) (2) EN(Glc)PVVHFFKNIVTPRTP
hMBP(83–99) (2) ENPVVHFFKNIVTPRTP
CSF114(Glc) (3) TPRVERN(Glc)GHSVFLAPYGWMVK
CSF114 (3) TPRVERNGHSVFLAPYGWMVK
CSF114(GlcAc4) (4) TPRVERN(GlcAc4)GHSVFLAPYGWMVK
CSF114(GlcNAc) (5) TPRVERN(GlcNAc)GHSVFLAPYGWMVK
CSF114(Glc4Glc) (6) TPRVERN(Glc4Glc)GHSVFLAPYGWMVK
[Ser7(Glc)]CSF114 (7) TPRVERS(Glc)GHSVFLAPYGWMVK
MBH36(Glc) (8) RGKYTYN(Glc)GITYEGR
MBH36 (8) RGKYTYNGITYEGR
[Thr9]CSF114(Glc) (9) TPRVERN(Glc)GTSVFLAPYGWMVK
[Thr9[CSF114 (9) TPRVERNGTSVFLAPYGWMVK
Ac-[c(Dap5, Asp10)]CSF114(Glc) (10) Ac-TPRV-c[Dap-RN(Glc)GHD]VFLAPYGWMVK
Ac-[c(Dap5, Asp10)]CSF114 (10) Ac-TPRV-c(Dap-RNGHD)VFLAPYGWMVK
Scramble CSF114(Glc) (11) LAKVSYN(Glc)FRMETRVGWHPVGP
Scramble CSF114(Glc) (11) LAKVSYNFRMETRVGWHPVGP
c, cyclo; Dap, 2,3-diaminopropionic acid; GlcAc4, tetraacetylated glucose;
Glc4Glc, cellobiose.
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Results
Design, Synthesis, and Screening of Glycopeptides Optimally Recog-
nizing AutoAbs in MS Patient Serum. We investigated the ability of
synthetic modified peptides specifically glycosylated tomimic struc-
tural features of neo-epitopes (self-Ags possibly recognized as
non-self-Ags after aberrant glycosylation) to be tested in MS. The
glucosylated analogue of the immunodominant epitope of MOG,
[Asn31(Glc)]hMOG (30–50) (peptide 1), which is able to detect
autoAbs in MS patients (16), and the inactive unglucosylated
analogue hMOG (30–50) (peptide 1) adopted similar solution
conformations. We concluded that the ability of the former mol-
ecule to detect autoAbs in MS was linked to characteristics other
than conformation and that the specific binding site on MOG
glycopeptide 1 was related to the N-linked glucose moiety (17).
We synthesized a series of peptide and glycopeptide sequences
unrelated toMOG to characterize the autoAb recognition in serum
of MS patients (Table 1). One such peptide was
[Asn84(Glc)]hMBP(83–99) (peptide 2), a glucosylated partial se-
quence of an immunodominant epitope of MBP, perhaps the most
studied MS candidate autoAg not naturally glycosylated. The
second was a completely unrelated sequence, termed CSF114(Glc)
(peptide 3). A structure-based design yielded CSF114(Glc) as an
artificial sequence characterized by a -turn structure, with a
conformational propensity to optimally expose the sugar moiety
(glucose) (22, 23).
We studied the IgG Ab titer to the three glycopeptides 1–3 and
to the corresponding unglycosylated sequences 1–3 (Table 1) by
SP-ELISA in a first group of 27 patients affected by clinically
definite MS (Fig. 1A). Because the sera of eight of 27 patients
showed increased titers when challenged with glycopeptide
CSF114(Glc), this molecule appears to be a preferred ligand for Ab
binding. Although we did not detect any Ab titer to the unglyco-
sylated peptides 1 and 3, in four of the above eight cases, we
observed reactivity to MOG glycopeptide 1 and to MBP glycopep-
tide 2. It is evident, therefore, that all glycopeptides containing
N-linked glucose identified high Ab titers, although CSF114(Glc)
detected the highest autoAb titer in MS serum (Fig. 1B).
Considering that SP-ELISA reflects essentially the relative af-
finity, which depends on the exposure of the epitope in the solid
phase conditions of the assay, we also investigated the absolute Ab
affinity in a competitive ELISA (19, 24) based on inhibition of
autoAbs in solution. In a set of threeMSpositive sera, glycopeptides
1–3 inhibited the binding of autoAbs to glycopeptide 1, giving rise
to similar inhibition curves (IC50 corresponding to 20–30 gml,
i.e., 107 M). In contrast, unglycosylated peptide 1 showed no
inhibitory activity. The data of a representative serum (Fig. 1C)
show that the three glycopeptides exhibited superimposable affinity
in competitive ELISA, despite the differences of apparent affinity
detected in SP-ELISA (Fig. 1B). This finding indicated that the
three glycopeptides had an identical epitope, which should contain
an Asn(Glc) residue.
Epitope Characterization. Role of the N-glucosyl moiety. By testing a
small focused library of CSF114 analogues characterized by glyco-
amino acid diversity (Table 1, compounds 4–7), we were able to
definitively determine that the minimal epitope had to contain an
Asn(Glc) moiety. In fact, glycopeptides lacking Asn(Glc) displayed
negligible inhibitory activity in competitive ELISA and failed to
detect IgG autoAbs in SP-ELISA (data not shown).
Role of the glycopeptide conformation. A second focused library of
glycopeptides based on structural diversity (Table 1, compounds
8–11) allowed us to determine the importance of the type I -turn
structure (25) for exposure of the minimal epitope (N-linked
glucose). Glycopeptides 8–10 and CSF114(Glc), all possessing the
-hairpin motif, revealed increased IgM andor IgG titers in
SP-ELISA (Fig. 2A). As expected, these glycopeptides, which
contained the minimal epitope Asn(Glc), displayed affinity for MS
autoAbs comparable to CSF114(Glc) (peptide 3) in a competitive
ELISA (Fig. 2B). Differently, glycopeptide 11, an unstructured
peptide scrambled in its amino acid sequence relative to
CSF114(Glc), did not recognize autoAbs in SP-ELISA because it
was unable to expose the epitope Asn(Glc) in the solid-phase
conditions of the assay (Fig. 2A). Structural studies byCD, one- and
two-dimensional protonNMR, andmolecularmodeling techniques
demonstrated that CSF114(Glc) possesses a -hairpin structure,
with the minimal epitope Asn(Glc) at position i  1 of a type I
-turn nicely exposed to Ab recognition (Fig. 3). It appears
therefore that the -turn conformation of CSF114(Glc) is funda-
mental for a correct exposure of the epitope containing Asn(Glc).
Validation Study in a Clinically Relevant Number of MS Patients:
Cross-Sectional and Long-Term Analysis.We extended the analysis of
Abs to CSF114(Glc) to a larger series of MS patients and controls
(531 sera in total). In the RR-MS population examined (n 250),
we detected increasedmean levels of IgMAb titers to CSF114(Glc)
(Table 2). The mean titers of anti-CSF114(Glc) IgM Abs were
increased in MS (mean titer, 943 488) versus the titers observed
in NBD (488  504; P  0.001, Mann–Whitney U test). The IgM
titers observed in OADwere significantly lower than in MS (467
366, P 0.001). Thus, the results in OAD were not different from
NBD. On the contrary, we detected increased anti-CSF114(Glc)
IgM Abs in patients affected by meningitis and encephalitis (IND)
in acute phase who were used as controls of a condition associated
with brain inflammation and myelin destruction (26). Therefore,
anti-CSF114(Glc) IgM Abs have a potential important diagnostic
value in MS, provided that a clinical evaluation exclude the
occurrence of acute IND.
Fig. 1. AutoAb recognition in RR-MSpatients’ sera. (A) IgGAb titers to glycopeptides 1, 2, and 3 and tounglycosylatedpeptides 1 and 3 in eight representative
RR-MS sera. (B) Mean IgG Ab titers reported in A to glycopeptides 1, 2, and 3. (C) Inhibition curves of Abs binding to glycopeptide 1 with glycopeptides 1, 2, and
3 and unglycosylated peptide 1 in a competitive ELISA. The results are expressed as the percentage of absorbance of a representative RR-MS serum of the five
of eight positive to glycopeptide 1 (ordinate axis). The concentrations of the peptides used as inhibitors are on the abscissa axis.
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We tested also anti-CSF114(Glc) IgG responses (Table 2).
Importantly, we found a very lowmeanAb titer inOAD (IgGmean
titer, 400 401) comparedwith themeanAb titer inRR-MS,NBD,
and IND, which was in the 800 range. All of the IgG responses
corresponded to the IgG2 subclass (data not shown).
We explored the potential of CSF114(Glc) to monitor disease
evolution. We followed longitudinally for up to 6 months a group
of 40 untreated RR-MS patients with an EDSS of3.5. The choice
to enroll patients in an untreated period was aimed at avoiding the
influence of therapies on autoAb levels. During the study, we
recorded the clinical activity, monthly MRI scans, and the anti-
CSF114(Glc) IgMand IgGAb titers. As an example, we present the
course of the Ab response to CSF114(Glc) in three representative
MSpatients (Fig. 4), two ofwhich (Fig. 4A andB) presented clinical
activity (Fig. 4, relapse at arrows) and Gd-enhancing positive brain
MRI lesions. For comparison, we present also an inactive patient
(Fig. 4C). The observed Ab response parallels the occurrence of
inflammatory brain lesions detected by MRI and the clinical
activity. In total, we detected Ab response to CSF114(Glc) in 16 of
40 (40%) patients showing Gd-positive MRI lesions.
Isolation and CNS Specificity of Anti-CSF114(Glc) AutoAbs from MS
Patients. Specific anti-CSF114(Glc) autoAbs were isolated from
MSpatients’ sera by using an immunoaffinity column that anchored
CSF114(Glc) to Sepharose. After loading sera, adsorbed IgM and
IgG autoAbs were eluted, which fully recovered their activity, as
determined by SP-ELISA. This experiment indicates that
CSF114(Glc) affinity columns provide a convenient one-step pro-
cedure to isolate autoAbs from CSF114(Glc)-positive MS sera.
To assess whether anti-CSF114(Glc) autoAbs recognized CNS
structures in situ, we tested sera from patients with either high Ab
titers (10 MS cases) or no reactivity to CSF114(Glc) (5 MS, 10
healthy subjects, and 5 patients affected by other neurological
diseases) by immunohistochemistry on sections fromnonpathologi-
cal human CNS specimens (20). All 10 CSF114(Glc)-positive sera
tested showed diffuse IgM immunostaining of CNS white matter,
particularly on myelin sheaths, and glial cells morphologically
resembling oligodendrocytes (Fig. 5A). Immunostaining for IgM
from all 20 CSF114(Glc)-negative cases gave no detectable signals
in CNS sections (Fig. 5B). We then explored which Ab fraction in
CSF114(Glc)-positive sera was responsible for CNS immunostain-
ing. For this purpose, we used CSF114(Glc)-specific IgG or IgM
affinity-purified Abs and IgG biotinylated isolated from two
CSF114(Glc)-positive MS sera. The immunostaining with
CSF114(Glc)-specific IgG or IgM (Fig. 5C) was comparable with
that of the respective sera, staining myelin, and small round glial
Table 2. Anti-CSF114(Glc) IgM titers, but not IgG, in RR-MS
patients are significantly increased compared with NBD
and OAD
RR-MS OAD NBD IND
IgM titers 943  488* 467  366 488  504 999  674*
IgM titers above
cut-off
51 (21) 0 (0) 10 (6) 7 (27)
IgG titers 816  814 400  401 866  872 854  801
IgG titers above
cut-off
65 (26) 3 (3) 36 (21) 9 (36)
Comparison of anti-CSF114(Glc) IgM and IgGmean titers in RR-MS patients
(n 250), OAD (n 90), NBD (n 166), and IND (n 25). Values for IgM and
IgG titers are means SD. IgM cut-off was set at themean 2 SD of NBD. IgG
cut-off was set at 1,000. Values in parentheses indicate percentages. *, P 
0.001 vs. NBD by Mann-Whitney U test.
Fig. 2. AutoAb recognition in MS patients’ sera to structurally diverse
glycopeptides. (A) IgM and IgG Ab titer (ordinates axis) to the glycopeptides
of the focused library based on structural diversity (peptides 8–11) and to
unglycosylated peptide 11 compared with glycopeptide 3 of two represen-
tative RR-MS sera (IgMIgG Abs) and one representative OAD serum. (B)
Inhibition curves of anti-CSF114(Glc) Abs with glycopeptides 8–11 and with
unglycosylated peptide 11, in comparison with CSF114(Glc) in a competitive
ELISA. The results are expressed as the percentage of absorbance of a repre-
sentative RR-MS serum (ordinate axis). The concentrations of the peptides
used as inhibitors are on the abscissa axis.
Fig. 3. Calculated structures of CSF114(Glc). Shown is a ribbon diagram of the
lowestenergyconformerof200calculatedstructuresofCSF114(Glc)derivedfrom
NMRdata.Themini-sheet involvingresidues4–5and10–11 isdepicted inviolet.
The turn motifs encompassing residues 6–9 and 14–17 are shown in yellow.
Heavy atoms are shown with the following color code: green, carbon; red,
oxygen; blue, nitrogen; and yellow, sulfur. Hydrogen atoms are not shown for
clarity. The NH2 and COOH termini are labeled N and C, respectively.
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cells in CNS white matter. At variance, Ig fractions depleted of
anti-CSF114(Glc) autoAbs gave no CNS immunoreactivity (Fig.
5D). We demonstrated the precise cellular distribution of the CNS
Ags recognized by anti-CSF114(Glc) autoAbs by double immuno-
fluorescence experiments. CSF114(Glc)-specific, biotinylated IgG
and IgM colocalized with MBP, an oligodendroglial phenotypic
marker on myelin sheaths, and at the surface of mature oligoden-
drocytes (Fig. 5 E–G). We did not observe any positive signal for
anti-CSF114(Glc)-specific biotinylated IgG in non-CNS human
tissues, which included sural nerve, muscle, liver, lung, and kidney
(Fig. 5 H–L), respectively, thus confirming the CNS specificity of
anti-CSF114(Glc) Abs.
Discussion
This study describes a synthetic glycopeptide termed CSF114(Glc),
which functions as an efficient antigenic probe to detect, isolate, and
characterize Abs as biomarkers of MS. CSF114(Glc) is a simple,
reliable, and efficient tool, which demonstrates that an aberrant
N-glucosylation is involved in autoAb recognition in MS.
The guiding principle for the selection of this antigenic probe
from focused peptide libraries of putative Ags was the efficient
detection of autoAbs present in patients’ sera. Within these librar-
ies, we designed peptides to bear small variations of amino acid
sequence or sugar moiety to rationally achieve optimal conforma-
tion of the epitope recognized by Abs.
This approach represents a radical departure from the conven-
tional one based on preselected myelin components, i.e., biochem-
ically isolated andor recombinant molecules that display variable
efficiency in the recognition properties for autoAbs.
A significant advantage offered by the synthetic approach is its
ability to overcome the difficulties inherent to the traditional
ones, which may not detect posttranslational modifications, such
as glycosylation of myelin proteins that could be affected by virus
andor bacterial infections or by defects in the glycosylation
pathway.
We demonstrated the value of CSF114(Glc) at several levels. At
the molecular level, the main feature of the synthetic Ag lies in the
glycopeptide fragment, which, by virtue of the peculiar type I
-turn structure, optimally exposes the minimal epitope Asn(Glc)
to autoAbs, recognizing them with high affinity and great speci-
ficity. At the cellular level, we proved the ability of CSF114(Glc)-
specific Abs to recognize myelin and oligodendrocyte autoAgs in
brain tissue. In parallel, we did not observe similar Ags in nonrel-
evant human tissues, such as sural nerve, muscle, liver, lung, and
kidney, thus suggesting that the Ag is brain-specific.
Finally, at the clinical level, CSF114(Glc) detected autoAbs in
MS serum by a simple SP-ELISA. We clearly demonstrated the
presence of high titers of anti-CSF114(Glc) IgM Abs in 21%
(51250) of the examined population of RR-MS patients (Table 2).
Fig. 4. Longitudinal study of three representative RR-MS patients. Course of
Ab response (IgM and IgG absorbance) to CSF114(Glc), EDSS, and number of
Gd-enhancingMRI brain lesions in three representativeMS patients. (A and B)
Two representative MS patients belonging to the longitudinal study group
presenting high anti-CSF114(Glc) Abs, clinical activity (relapse at arrows), and
brain MRI lesions. (C) An inactive patient.
Fig. 5. CNS specificity of anti-CSF114(Glc) autoAbs. (A and B)
Immunoperoxidase reaction for IgMontoCNS sections reveals
diffuse staining in the white matter on myelin and on small
glial cells, morphologically resembling oligodendrocytes, af-
ter incubation of CSF114(Glc)-positiveMS serum (A) but not of
CSF114(Glc)-negative serum (B). (C) Myelin and glial cells of
CNS white matter were also immunostained by CSF114(Glc)-
specific anti-CSF114(Glc) IgG Abs affinity-purified from anMS
patient. (D) After depletion of anti-CSF114(Glc)-specific Ig, no
detectable staining was observed for IgM. (E and F) The dou-
ble immunofluorescence with biotinylated anti-CSF114(Glc)
IgGAbs from the sameMS patient [Texas red (E)] andwith the
oligodendroglial cell marker MBP [fluorescein (F)] showed
that Ags recognized by anti-CSF114(Glc)-specific IgGAbswere
localized on myelin sheaths and on the surface of oligoden-
drocytes. (G) Merged image of E and F. (H–L) No positive
signals for anti-CSF114(Glc)-specific IgGwere detected in non-
CNS human tissues, which included sural nerve (H), muscle (I),
liver (J), lung (K), and kidney (L). (Bars, 80 m.)
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The specificity was highest for IgM autoAbs as shown by the higher
percentage of MS patients recognized by our Ag relative to NBD
(P  0.0001) or OAD (rheumatoid arthritis and systemic lupus
erythematosus), in which the Ab titer was negligible (P 0.001). In
accordancewith our results, recent reports have greatly emphasized
the relevance of IgM for the autoAb response in MS (11, 27). The
biological importance of IgM binding to different glycosylated
epitopes was further confirmed in experimental models of demy-
elination when these Abs are synthesized within the CNS (28).
In our view, the IgG titer as detected by CSF114(Glc) appears to
be unspecific because it detects a ‘‘noise’’ level in all groups
examined except OAD. Perhaps this noise originates from carbo-
hydrate Ags, which are important components of both innate and
adaptive antimicrobial immunity. The high rate of positive results
among NBD for IgG autoAbs is in line with recently reported data
indicating that specific autoAbs precede by several years the onset
of autoimmune diseases (29). Consequently, NBD’s single serum
samples are a less significant control as compared with clinically
characterized patients affected by other autoimmune conditions in
which anti-CSF114(Glc) IgG are virtually absent.
Because many microbial oligosaccharide structures are also
expressed in humans, immune responses directed to these struc-
tures commonly occur as memory-protective IgG responses in
healthy subjects after common infection. The predominant IgM
and IgG2 response detected in the present study seems to be
reminiscent of a T cell-independent B activation that is known to
be stimulated by many nonproteic Ags (30).
Moreover, the presence of anti-CSF114(Glc) Abs in patients
affected by meningitis and encephalitis (IND) does not affect the
specificity of our tool, but, on the contrary, this result strongly
supports the usefulness of our test. In fact, it is possible that the
detected autoAbs are a measurement of a systemic immune re-
sponse during a neuroinflammatory condition, monitoring major
tissue inflammation, demyelination, and necrosis processes (26).
Because sera from IND were collected in the acute phase, the high
anti-CSF114(Glc) Ig titer will decline in analogy to that occurring
for other anti-myelin autoAbs (31).
Although CSF114(Glc) as an Ag was less discriminating toward
IgG response, we importantly demonstrated in the longitudinal
analysis of MS patients that the combined IgM and IgG Ab titer is
instrumental in monitoring disease activity. We followed for up to
6months a consistent group of untreatedMS patients (n 40) with
a clearly defined disease by using the ELISA assay on sera with
CSF114(Glc) as an Ag. The IgM and IgG Ab response to
CSF114(Glc) recorded at regular intervals paralleled the occur-
rence of MRI lesions and disease progression in 40% of the
patient population (1640). These results showed the potent value
of IgM and IgG Ab titers in detecting disease activity. In this
instance, IgG determination has a high prognostic value.
Thus, the synthetic glycopeptide CSF114(Glc) appears to delin-
eate a subgroup of RR-MS patients in which disease activity, MRI
lesions, and, therefore, demyelination is associated with an in-
creased titer of Abs to CSF114(Glc). Moreover, because increased
responses to this synthetic Ag ran concurrently with relapsing
episodes, the assay may assume a predictive value for disease
progression.
Up to now only low-affinity anti-myelin autoAbs have been
detected in sera of MS patients. Although anti-myelin proteins
(MBP or MOG) Abs were reported as possible diagnostic tools for
prediction of development of clinically established MS after the
appearance of the first clinical symptoms (11), no correlation with
disease activity and disability progression has been demonstrated
(7). Moreover, other authors found by techniques other than
ELISA (radio-binding assay and Western blot analysis) a similar
frequency of low-affinity anti-MOGAbs in sera ofMS patients and
healthy subjects (13, 14).
Considering the pathophysiological heterogeneity of MS,
CSF114(Glc) could help to characterize theMS subtype associated
with Ab-mediated demyelination, having an important impact in
diagnosis and prognosis of the disease as well as on the selection of
therapy in an effort to provide individualized treatment (32).
Therefore, our results demonstrate that CSF114(Glc) can be
used in a simple ELISA test as the first MS antigenic probe for
detecting specific autoAbs that can serve as reliable biomarkers for
the practical evaluation of the disease activity in a subpopulation of
MS patients.
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